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and Charles H. Webb, MD
Noncardiovascular adverse effects associated with amiodarone result in substantial mor-
bidity. Adverse effects involving the skin, liver, thyroid, and lungs have been reported in
as many as 57%, 55%, 11%, and 13% of patients, respectively. Although risk factors
for some amiodarone-induced adverse effects have been identified, risk factors for these
specific side effects have not been systematically evaluated. Therefore, risk factors for
development of amiodarone-induced dermatologic, hepatic, thyroid, or pulmonary ad-
verse effects were identified using univariate analysis in 44 patients receiving the drug
for supraventricular or ventricular arrhythmias (mean duration of therapy 99.5 ± 110.8
weeks). Dermatologic side effects occurred in 4 (9.1%) patients. Patients who experienced
dermatologic side effects were younger than patients who did not (mean age, 48.3 ± 15.8
years versus 60.1 ± 9.5 years. respectively; P = .03). Patients younger than 60 years of age
were more likely to develop photosensitivity or blue-gray skin discoloration than those
aged 60 or older (P = .05). Hepatic adverse effects occurred in 3 (6.8%) patients. Left
ventricular ejection fraction was lower in those who developed hepatic adverse effects
than in those who did not (15.0 ± 4.0% versus 39.1 ± 13.9%, P = .005). Adverse thyroid
effects occurred in 6 (13.6%) patients; and pulmonary fibrosis occurred in 2 (4.5%) pa-
tients. No specific risk factors for adverse thyroid effects or pulmonary fibrosis were re-
vealed. In conclusion, age less than 60 may be a risk factor for amiodarone-induced der-
matologic adverse effects, whereas severely depressed left ventricular ejection fraction
may be a risk factor for hepatic side effects associated with amiodarone.
T he adverse effect profile of the antianrhythmic
agent amiodarone has been well described.1 The
overall incidence of adverse effects attributable to
amiodarone therapy ranges from 34 to 93%, and in 1
to 26% of patients receiving amiodarone therapy
must be discontinued as a result of side effects.1 Al-
though amiodarone may produce cardiovascular ad-
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verse effects such as exacerbation of heart failure
and proanrhythmia, these effects occur rarely. Non-
cardiovascular side effects associated with amiodar-
one-such as those involving the gastrointestinal
tract, central nervous system, liver, thyroid, skin,
and lungs-occur more commonly, and are more
likely to limit use of the drug.1 Although amiodarone
is a highly effective agent, the noncardiovascular ad-
verse effect profile has resulted in the recommenda-
tion that its use be limited to patients with arrhyth-
mias refractory to therapy with other antiarnhythmic
agents.2’3
Despite these recommendations, some authors
have advocated study4 or use5 of amiodarone earlier
in the course of certain arrhythmias, because of con-
cerns about the safety of antiarrhythmic drugs from
other Vaughan Williams classes.67 In addition, pre-
liminary data suggest that, unlike other antiarrhyth-
mic agents such as encainide or flecainide,8 amiodar-
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one may result in decreased mortality in patients
with asymptomatic complex ventricular ectopic ac-
tivity after acute myocardial infarction.9 If these
data are confirmed in continuing larger studies in
this population and/or in patients with left ventric-
ular dysfunction,12 use of amiodarone is likely to be-
come more widespread, and amiodarone may be
given earlier in the course of arrhythmia therapy
than is currently recommended. Thus, with the rel-
atively high frequency of side effects associated with
this agent, identification of risk factors for amiodar-
one-induced adverse effects is desirable, so that pa-
tients at risk may be monitored more closely, protec-
tive measures taken, and/or alternative therapy se-
lected if necessary.
Risk factors for the development of certain adverse
effects associated with amiodarone have been iden-
tified. Cumulative amiodarone dose and duration of
therapy appear to be risk factors for many of the
drug’s adverse effects.13’14 Pulmonary fibrosis,15 some
central nervous system effects,13’16 and corneal mi-
crodeposits” appear to be associated with high daily
amiodarone doses. Some adverse effects caused by
the drug, such as those involving the central nervous
system, are often associated with elevations in serum
amiodarone/desethylamiodarone (DEA) concentra-
tions.18 Risk factors for other specific noncardiovas-
cular adverse effects caused by amiodanone have not
been systematically evaluated.
Dermatologic, hepatic, thyroid, and pulmonary ad-
verse effects associated with amiodarone have been
reported in as many as 57%, 55%, 11%, and 13% of
patients, respectively. 19-22 However, despite high fre-
quencies of these side effects, risk factors have not
been well-studied. The purpose of this study is to de-
termine risk factors for amiodarone-associated den-
matologic, hepatic, thyroid, on pulmonary adverse
effects.
hepatic abnormalities, including elevations in serum
aspartate aminotransferase, alanine aminotransfer-
ase, alkaline phosphatase, r-glutamyltransfenase, or
bilirubin greater than twice baseline, with or with-
out symptomatic liven dysfunction; (3) thyroid toxi-
cicty, including elevations or reductions in serum L-
thyroxine (T4), 3,5,3’-triiodo-L-thyronine (T3), T3
resin uptake, or thyroid stimulating hormone, with
or without symptomatic hypo- or hyperthyroidism;
and (4) pulmonary toxicicty, specifically pulmonary
fibrosis or interstitial pneumonitis.
The following patient characteristics were evalu-
ated as potential risk factors for these amiodarone-
induced adverse effects: gender; age; race; left ven-
tricular ejection fraction (EF), as determined by left
ventriculognaphy, 2-dimensional echocardiognaphy,
or radionuclide ventniculography; congestive heart
failure, as determined by patient history and physi-
cal examination; coronary artery disease; serum
amiodarone concentration at the time of each ad-
verse effect, and combined serum amiodarone/DEA
concentration at the time of each adverse effect.
Data Analysis
Risk factors for all categories of adverse effects were
determined using univaniate analysis. Nonparamet-
nc data were analyzed using chi-square analysis, un-
less expected cell frequencies were less than 5, in
which case the Fisher exact test was used. Paramet-
ric data were analyzed using the Student unpaired t
test, with the exception of cumulative amiodarone
dose and duration of amiodarone therapy, which
were not normally distributed, and therefore were
analyzed using the Mann-Whitney test. For all anal-
yses, P < .05 was considered suggestive,23 and P <
.006 (.05/9, adjusted for multiple comparisons) was
considered significant.
METHODS RESULTS
Patient Population Patient Characteristics
This study was a retrospective review of adverse
effect data collected prospectively from a series of 44
consecutive patients referred to the Cardiac Electro-
physiology Service at Henry Ford Hospital, who re-
ceived amiodarone for the management of cardiac
arrhythmias.
Data Collection
Specific noncandiovascular adverse effects evaluated
were defined as follows: (1) dermatologic toxicity:
blue-gray skin discoloration or photosensitivity; (2)
Characteristics of the 44 patients included in this
study are presented in Table I. Twenty-one (47%) pa-
tients were older than 60 years of age. The majority
of patients had coronary artery disease and/or con-
gestive heart failure; 24 (55%) patients had EF of 40%
or lower. Almost all patients were receiving amio-
darone for the management of ventricular arrhyth-
mias. Most patients had arrhythmias refractory to
therapy with other agents; 38 (86%) patients had re-
ceived prior therapy with 2 or more antianrhythmic
drugs or drug combinations, which were either in-
effective or intolerable.
TABLE II
Risk Factors for Adverse Dermatologic Effects
CAD = coronary artery disease; CHF = congestive heart failure; EF = left ven-
tricular ejection fraction; Ml = myocardial infarction.
Values in parentheses are ranges.











Mean EF(%) 37± 15(15-70)
Presenting arrhythmia (n)
Ventricular tachycardia 29
Sudden cardiac death 11
Ventricular premature beats 1
Atrial fibrillation 1
Syncope 2
Mean no. of antiarrhythmic drugs
that failed 3.1 ± 1.5(0-6)




Dermatologic adverse effects occurred in 4 (9.1%) pa-
tients (Table II). One patient had blue-gray skin dis-
coloration, and 3 patients experienced photosensi-
tivity reactions. Patients with dermatologic reactions
to amiodarone tended to be younger than those who
did not experience these adverse effects; patients
younger than 60 years were more likely to develop
these side effects than those 60 years or older (P =
.05).
Hepatic Adverse Effects
Adverse hepatic effects occurred in 3 (6.8%) patients
(Table III). Two patients developed asymptomatic el-
evations in liven function tests: In one, serum ‘r-glu-
tamyltransferase concentration became elevated
more than 15 times baseline (to a maximum of 640
U/L), and total serum bilirubin concentration be-
came elevated to approximately twice baseline
(maximum of 1.9 mg/dL). The other patient devel-
oped elevation in serum alkaline phosphatase con-
centration of more than 5 times baseline (maximum
of 613 U/L). The third patient developed clinical he-
patic dysfunction manifested by abdominal tender-





Male/female 4:0 29:11 0.56
Age(yr) 48.3± 15.8 60.1±9.5 0.03
Whites/Blacks 4:0 34:6 1.00
Duration of
therapy(wk) 74.0± 59.3 88.1 ± 108.9 0.58
Cumulative
dose(g) 211.8± 188.6 194.5 ±236.2 0.64
EF(%) 48.0± 18.1 36.7 ± 14.5 0.21
CHF 2(50%) 32 (80%) 0.22
Serum A
(g/mL) N/A* 1.8 ± 0.9 N/A
Serum A + DEA
(ig/mL) 3.2 ± 0.7 2.2 ± 1.0 0.18
AE adverse effects; A = amiodarone; N/A = not applicable; DEA = desethy-
lamiodarone.
* Serum A concentrations reported only in combination with DEA in these
patients.
dosage. Left ventricular EF was significantly lower in
patients who developed amiodarone-associated he-
patic adverse effects than in those who did not.
Thyroid Adverse Effects
Adverse thyroid effects occurred in 6 (13.6%) pa-
tients (Table IV). Four patients developed asymptom-
TABLE III





Male/female 2:1 31:10 1.00
Age(yr) 68.3 ±2.5 58.3± 10.6 0.11
Whites/Blacks 3:0 35:6 1.00
Duration of
therapy(wk) 49.2 ±35.8 97.2±112.6 0.78
Cumulative
dose(g) 138.2±88.7 224.3±271.9 1.00
EF(%) 15.0±4.0 39.1 ± 13.9 0.005
CHF 3(100%) 31(76%) 1.00
Serum A
(sg/mL) N/AC 1.8 ± 0.9 N/A
Serum A + DEA
(sg/mL) 2.4 ± 0.4 2.3 ± 1.0 0.89
Abbreviations are the same as in Table II.
Serum A concentrations reported only in combination with DEA in these pa-
tients.
factor for amiodarone-associated pulmonary toxic-
TABLE V
Risk Factors for Pulmonary Fibrosis
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TABLE IV





Male/female 5:1 28:10 1.00
Age(yr) 53.5± 16.2 59.8± 9.4 0.18
Whites/Blacks 6:0 32:6 0.57
Duration of
therapy(wk) 153.9± 133.1 75.4±89.1 0.13
Cumulative
dose (g) 389.2 ± 419.8 172.8 ± 209.1 0.18
EF (%) 46.6 ± 22.6 36.2 ± 13.4 0.14
CHF 3(50%) 31(82%) 0.23
Serum A
(fsg/mL) 2.1±0.5 1.8±0.9 0.65
SerumA+DEA
(sg/mL) 3.0 ± 0.4 2.2 ± 1.0 0.27
Abbreviations are th e same as in Table II.
atic elevation of serum T4 concentrations; 1 patient
developed asymptomatic reduction in serum thy-
roid-stimulating hormone concentrations. One pa-
tient developed severe hyperthyroidism requiring
therapy with pnopylthiouracil. None of the factors
evaluated was significantly different in patients who
experienced adverse thyroid effects compared with
those who did not.
for denmatologic toxicity, whereas severely de-
pressed left ventricular EF was a significant risk fac-
tor for development of adverse hepatic effects.
Dermatologic Adverse Effects
Age was suggestive as a risk factor for dermatologic
adverse reactions associated with amiodarone. Pa-
tients who experienced these adverse reactions were
younger than those who did not; patients younger
than 60 years of age appeared to be at highest risk.
Similarly, Hyatt and associates24 noted a lower fre-
quency of adverse denmatologic reactions associated
with amiodarone in elderly patients than previously
reported in younger patient populations.19 This may
be due to greater exposure to the sun in younger pa-
tients than in the elderly. In addition to this factor, it
appears likely that duration of therapy and cumula-
tive amiodarone dose are also risk factors for derma-
tologic adverse effects.19 In this study, age-associated
increases in the risk of dermatologic side effects were
independent of duration of therapy and cumulative
dose; these parameters were not significantly differ-
ent in patients who experienced adverse dermato-
logic reactions compared with those who did not,
likely because the mean duration of therapy in pa-
tients in this study was less than two years.19
Hepatic Adverse Effects
Mean left ventricular EF was significantly lower in
patients who developed hepatic adverse effects com-
Pulmonary Adverse Effects
Two patients (4.5%) developed pulmonary fibrosis
during therapy with amiodarone (Table V). None of
the characteristics evaluated was revealed as a risk
ity.
DISCUSSION
Amiodarone is effective for the management of a va-
riety of cardiac arrhythmias, particularly for those
refractory to therapy with other agents. For this rea-
son, and because of concerns about the safety of class
I antiarrhythmic agents, amiodarone use continues
to increase. However, amiodarone administration re-
sults in a relatively high frequency of noncardiovas-
cular adverse effects. Prediction of patients likely to
experience specific adverse effects may be clinically
useful, so that such patients may be monitored more
closely, preventive measures taken, or alternative
therapy selected if appropriate. In the present study,







Male/female 1:1 32:10 0.44
Age (yr) 66.5 ± 0.7 58.6 ± 10.7 0.31
Whites/Blacks 2:0 36:6 1.00
Duration of
therapy (wk) 57.2 ± 46.9 99.8 ± 112.6 0.98
Cumulative
dose(g) 154.7± 113.8 231.2±269.7 0.98
EF(%) 34.5±21.9 37.6± 14.7 0.78
CHF 2(100%) 32 (76%) 1.00
Serum A
(1ig/mL) N/A* 1.8 ± 0.9 N/A
SerumA+DEA
(zg/mL) 2.4 ± 0.3 2.3 ± 1.0 0.89
Abbreviations are th e same as in Table II.
* Serum amiodarone concentrations reported only in combination with DEA in
these patients.
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pared with those who did not. This may be due to
underperfusion or congestion of the liver in patients
with low cardiac outputs associated with extremely
low left ventricular EFs. Harris and colleagues19
found significant correlations between serum amio-
darone and DEA concentrations and elevations in se-
rum aspartate transaminase concentrations. In the
present study, combined serum amiodarone/DEA
concentrations were not different in those with he-
patic dysfunction compared with those without.
Thyroid Adverse Effects
Risk factors for thyroid adverse effects associated
with amiodarone were not revealed in this study. Al-
though previous investigators have suggested that
older patients might be at increased risk for amiodar-
one-induced thyroid disease,19 our findings did not
confirm this. Other investigators have also been un-
able to identify predictive factors for amiodarone-in-
duced thyroid disease.25 Baerman and associates26
found no correlation between serum amiodarone or
DEA concentrations and serum reverse T3 concen-
trations. In the present study, serum amiodanone on
DEA concentrations were not different in those with
thyroid disease than in those without. Trip and Wier-
singa27 reported that the development of amiodar-
one-induced hypothyroidism was related to the pres-
ence of pretreatment microsomal and/or thynoglob-
wlin antibodies. In the same study, predictive factors
for the development of amiodarone-induced thyro-
toxicity could not be identified.
Pulmonary Adverse Effects
Risk factors for the development of amiodarone-in-
duced pulmonary fibrosis were not revealed in this
study. However, the fact that only two patients de-
veloped pulmonary fibrosis may have precluded
identification of risk factors. Previous investigators
have suggested that patients with abnormal pretreat-
ment lung function may be at risk for pulmonary tox-
icity associated with amiodarone.28 In addition, the
risk of pulmonary toxicity may be related to the du-
ration of amiodarone therapy and/or cumulative
amiodarone dose,15 although studies have been in-
consistently successful at correlating these factors
with the development of amiodarone-induced pul-
monary adverse effects.18’29
Limitations
Interpretation of the study results is limited by the
retrospective nature of the data collection. However,
all patients reported herein were observed prospec-
tively for the development of adverse effects. In ad-
dition, because of the retrospective nature of the
study, it was nonrandomized. Therefore, some treat-
ment bias may exist; the electrophysiologist manag-
ing these patients may have avoided amiodarone or
used lower doses in certain patients considered at
higher risk for toxicity, such as the elderly on those
with poor left ventricular function. The sample size
was relatively small, and small numbers of patients
developed specific amiodarone-induced noncardio-
vascular adverse events. Nevertheless, risk factors
were identifiable for specific toxicities. It is possible
that some existing risk factors for these adverse
effects were not identified owing to small numbers of
patients in certain side effect groups (type II error).
CONCLUSIONS
Amiodarone-induced dermatologic, hepatic, thy-
roid, or pulmonary adverse effects occur relatively
frequently. However, risk factors have been identi-
fied that may help to predict the development of
some specific noncandiovascular adverse effects. Age
less than 60 years may be a risk factor for dermato-
logic adverse effects. Severely depressed left ventric-
ular ejection fraction may be a risk factor for eleva-
tions in liver function tests and hepatic toxicity. Fur-
ther study in larger patient populations is required to
confirm these findings.
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